Levi & Korsinsky, LLP announces that an AMRN class action lawsuit has been filed on behalf of investors who purchased Amarin Corporation Plc (AMRN) securities between December 5, 2018, and June 21, 2021. For more on the AMRN Lawsuit please contact us today.

According to the Amarin lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) there was an increasingly high risk that certain of Amarin’s patents would be invalidated; (ii) once the District Court invalidated certain of Amarin’s patents, there was little to no chance of reversing that ruling; (iii) the Company’s litigation was preventing it from effectuating a successful takeover; (iv) Defendants were downplaying the true threat the ongoing abbreviated new drug application litigation posed to the Company’s business and future prospects; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE AMRN CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Amarin you have until December 23, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com